A new report from BRG suggests a significant uptick in transaction activity is expected across the U.S. health care and life sciences sectors in 2025, following slower deal volumes in 2023 and 2024. The findings stem from BRG's "2025 US Healthcare & Life Sciences Transactions Outlook," which surveyed more than 150 executives and decision-makers from provider, payer, and life sciences organizations, supplemented by expert interviews.
After a period dampened by inflation, rising interest rates, and regulatory pressures—which saw global healthcare M&A volume drop nearly 30% from its 2021 peak—industry players are signaling readiness to pursue deals again. This anticipated rebound presents potential opportunities for consultants advising on strategy, M&A, integration, and operational improvements.
To continue reading, become an ALM digital reader
Benefits include:
- Authoritative and broad coverage of the business of consulting
- Industry-leading awards programs like Best Firms to Work For, Global Leades and Rising Stars
- An informative newsletter that goes into the trends shaping the industry
- Critical coverage of the employee benefits and financial advisory markets on our other ALM sites, BenefitsPRO and ThinkAdvisor
Already have an account? Sign In Now
